Literature DB >> 17115103

Perioperative interstitial brachytherapy for soft tissue sarcomas: prognostic factors and long-term results of 155 patients.

Siddhartha Laskar1, Gaurav Bahl, Ajay Puri, Manish G Agarwal, MaryAnn Muckaden, Nikhilesh Patil, Nirmala Jambhekar, Sudeep Gupta, Deepak D Deshpande, Shyam K Shrivastava, Ketayun A Dinshaw.   

Abstract

BACKGROUND: The goal of this study was to evaluate the efficacy of temporary interstitial brachytherapy (BRT) for patients undergoing combined modality management of soft tissue sarcomas (STS).
METHODS: From January 1990 to December 2003, 155 adults 18-88 years of age (median = 42 years) with STS who had received BRT as part of locoregional treatment were included in this review. Sixty-four percent were males. Sixty-nine percent had primary lesions. Sixty percent had lesions involving the lower extremities. Spindle cell sarcoma (28%) and synovial sarcoma (16%) were the most common histologic types and 51% had grade III lesions. Treatment included wide local excision of primary tumor with BRT with or without external beam radiotherapy (EBRT).
RESULTS: After a median followup of 45 months, the local control (LC), disease-free survival (DFS), and overall survival (OS) for the entire cohort was 71%, 57%, and 73%, respectively. DFS was superior for superficial tumors compared with that for deep tumors (96% vs. 54%, P =.02). Patients with a tumor less than 5 cm had superior OS (88% vs. 63%, P =.05). Cumulative radiotherapy dose greater than 60 Gy had a significant positive impact on LC (P = .003), DFS (P =.003), and OS (P =.048). Subcutaneous fibrosis (21%) was the major complication.
CONCLUSIONS: Temporary perioperative iridium-192 interstitial BRT with or without EBRT after function-preserving surgery results in satisfactory outcome in patients with STS. Both low dose rate and high dose rate BRT are equivalent in terms of disease control and complications when used alone or in combination with EBRT. BRT results in fewer complications compared with the combination of BRT and EBRT.

Entities:  

Mesh:

Year:  2006        PMID: 17115103     DOI: 10.1245/s10434-006-9137-2

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  7 in total

1.  Early complications of high-dose-rate brachytherapy in soft tissue sarcoma: a comparison with traditional external-beam radiotherapy.

Authors:  Cynthia L Emory; Corey O Montgomery; Benjamin K Potter; Martin E Keisch; Sheila A Conway
Journal:  Clin Orthop Relat Res       Date:  2012-03       Impact factor: 4.176

2.  (125)I brachytherapy seeds implantation for inoperable low-grade leiomyosarcoma of inferior vena cava.

Authors:  Yuliang Li; Yongzheng Wang; Bin Liu; Zheng Li; Wujie Wang
Journal:  Korean J Radiol       Date:  2013-02-22       Impact factor: 3.500

3.  Multimodality management of extremity soft tissue sarcomas-an Indian perspective.

Authors:  Ajay Puri; Ashish Gulia
Journal:  Indian J Surg Oncol       Date:  2012-01-31

4.  Management of extremity soft tissue sarcomas.

Authors:  Ajay Puri; Ashish Gulia
Journal:  Indian J Orthop       Date:  2011-07       Impact factor: 1.251

5.  Adjuvant high dose rate brachytherapy for soft tissue sarcomas: initial experience report.

Authors:  Julie A Bradley; Sara H Kleinman; Jason Rownd; David King; Donald Hackbarth; Robert Whitfield; Dian Wang
Journal:  J Contemp Brachytherapy       Date:  2011-03-31

6.  Retrospective Analysis of Spectrum of Presentation and Treatment Outcome in Extremity Sarcomas: A Single-Centre Experience.

Authors:  Saurabh Bansal; Kunal Das; Navneet Jain; Vipul Nautiyal; Meenu Gupta; Nadia Shirazi; Sanjiv Verma; Mushtaq Ahmad; Sunil Saini
Journal:  Sarcoma       Date:  2018-04-01

7.  Adjuvant radiotherapy with brachytherapy boost in soft tissue sarcomas.

Authors:  Annalisa Cortesi; Andrea Galuppi; Rezarta Frakulli; Alessandra Arcelli; Fabrizio Romani; Gian Carlo Mattiucci; Giuseppe Bianchi; Stefano Ferrari; Andrea Ferraro; Andrea Farioli; Marco Gambarotti; Alberto Righi; Gabriella Macchia; Francesco Deodato; Savino Cilla; Milly Buwenge; Vincenzo Valentini; Alessio Giuseppe Morganti; Davide Donati; Silvia Cammelli
Journal:  J Contemp Brachytherapy       Date:  2017-06-05
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.